Progressive multifocal leukoencephalopathy after fingolimod treatment. by Berger, Joseph R et al.
UC Irvine
UC Irvine Previously Published Works
Title
Progressive multifocal leukoencephalopathy after fingolimod treatment.
Permalink
https://escholarship.org/uc/item/3nf0j9qr
Journal
Neurology, 90(20)
ISSN
0028-3878
Authors
Berger, Joseph R
Cree, Bruce A
Greenberg, Benjamin
et al.
Publication Date
2018-05-01
DOI
10.1212/WNL.0000000000005529
License
CC BY 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE OPEN ACCESS
Progressive multifocal leukoencephalopathy after
ﬁngolimod treatment
Joseph R. Berger, MD, Bruce A. Cree, MD, PhD, Benjamin Greenberg, MD, Bernhard Hemmer, MD,
Brian J. Ward, MDCM, Victor M. Dong, MD, and Martin Merschhemke, MD
Neurology® 2018;90:e1815-e1821. doi:10.1212/WNL.0000000000005529
Correspondence
Dr. Berger
joseph.berger@
uphs.upenn.edu
Abstract
Objective
We describe the characteristics of the 15 patients with ﬁngolimod-associated progressive
multifocal leukoencephalopathy (PML) identiﬁed from the Novartis data safety base and
provide risk estimates for the disorder.
Methods
The Novartis safety database was searched for PML cases with a data lock point of August 31,
2017. PML classiﬁcation was based on previously published criteria. The risk and incidence
were estimated using the 15 patients with conﬁrmed PML and the overall population of patients
treated with ﬁngolimod.
Results
As of August 31, 2017, 15 ﬁngolimod-treated patients had developed PML in the absence of
natalizumab treatment in the preceding 6 months. Eleven (73%) were women and the mean
age was 53 years (median: 53 years). Fourteen of the 15 patients were treated with ﬁngolimod
for >2 years. Two patients had confounding medical conditions. Two patients had natalizumab
treatment. This included one patient whose last dose of natalizumab was 3 years and 9 months
before the diagnosis of PML. The second patient was receiving ﬁngolimod for 4 years and 6
months, which was discontinued to start natalizumab and was diagnosed with PML 3 months
after starting natalizumab. Absolute lymphocyte counts were available for 14 of the 15 patients
and none exhibited a sustained grade 4 lymphopenia (≤200 cells/μL).
Conclusions
The risk of PML with ﬁngolimod in the absence of prior natalizumab treatment is low. The
estimated risk was 0.069 per 1,000 patients (95% conﬁdence interval: 0.039–0.114), and the
estimated incidence rate was 3.12 per 100,000 patient-years (95% conﬁdence interval:
1.75–5.15). Neither clinical manifestations nor radiographic features suggested any unique
features of ﬁngolimod-associated PML.
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Progressive multifocal leukoencephalopathy (PML) is a rare
opportunistic infection of the CNS caused by reactivation of
a latent John Cunningham virus (JCV), with a prevalence of
0.2 cases per 100,000 persons in the general population.1 In
2005, PML was conﬁrmed in 3 patients participating in
natalizumab clinical trials of multiple sclerosis (MS)2,3 and
Crohn disease,4 disorders that were not previously associated
with PML. As of August 2017, 749 conﬁrmed cases of PML
associated with natalizumab have been reported5 and, further,
in 5 dimethyl fumarate–treated patients with MS.6 This has
raised the possibility that there has been an increased risk of
PML in patients with MS treated with immunosuppressive or
immunomodulatory agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator
approved for the treatment of relapsing forms of MS. Fin-
golimod prevents the egress of T and B lymphocytes from
lymph nodes and reduces the inﬁltration of autoaggressive
cells into the CNS.7,8
Although peripheral blood lymphocyte counts declined by 73%
from baseline values within 1 month of drug initiation,9,10 con-
sistent with the pharmacodynamic action of ﬁngolimod, serious
or opportunistic infections have only been infrequently observed
in the postmarketing setting. To date, no correlation has been
shown between absolute lymphocyte counts and the incidence
of serious or opportunistic infections. Since 2015, PML cases not
attributed to prior exposure to immunosuppressants have been
reported in ﬁngolimod-treated patients. The US prescribing in-
formation was subsequently updated to include opportunistic
infections including PML.11 Herein, we describe the character-
istics of 15 PML cases reported in ﬁngolimod-treated patients
with MS.
Methods
The Novartis safety database was searched for PML cases
using the following search terms (MedDRA [Medical Dictio-
nary for Regulatory Activities], version 19.1) with a data lock
point of August 31, 2017: progressive multifocal leukoence-
phalopathy, leukoencephalopathy, leukoencephalomyelitis,
and JC virus granule cell neuronopathy. The PML cases were
classiﬁed as “deﬁnite,” “probable,” “possible,” or “not PML”
based on the criteria presented by Berger et al. in 2014,12 by an
adjudication committee comprising experts in MS and PML.
This classiﬁcation is based on JCV DNA PCR status of CSF,
MRI ﬁndings, and clinical presentation.
Overall patient exposure estimates were determined based on
a combination of patient exposure to ﬁngolimod in clinical
trials together with an estimate of postmarketing patient ex-
posure (which is calculated based on worldwide sales volume
in kilograms of active substance sold during the period and the
deﬁned daily dose of 0.5 mg).
The incidence of PML in patients treated with ﬁngolimod was
estimated using the 15 conﬁrmed PML cases and an overall
population of patients treated with ﬁngolimod. Patient char-
acteristics were compiled based on the pharmacovigilance
reports from the treating physicians held in theNovartis safety
database, and patient identiﬁers are not revealed.
Data availability
These data are not from a clinical trial or speciﬁc study setup.
It is rather based on postmarketing spontaneous reports made
to Novartis in the context of routine pharmacovigilance. This
reporting comes from various regions/countries with their
respective data privacy laws. Data available in the Novartis
safety database have been used to describe the carefully dei-
dentiﬁed individual cases, and as such, no further data will be
shared in either a repository or on request.
Results
In total, 15 conﬁrmed PML cases—12 “deﬁnite” and 3
“probable”—for which prior immunotherapy is not impli-
cated, were identiﬁed in the real-world setting. Based on data
from 15 conﬁrmed PML cases associated with ﬁngolimod
treatment alone, the estimated risk is 0.069 per 1,000 patients
(95% conﬁdence interval [CI]: 0.039–0.114) and the esti-
mated incidence rate is 3.12 per 100,000 patient-years (95%
CI: 1.75–5.15). Details of the clinical features of the 15 PML
cases are shown in the table.
Demographics and baseline characteristics
The patients were geographically dispersed across Europe (n
= 6), North America (n = 5), and Asia (n = 4). Of the 15
patients, 11 were women. The mean patient age was 53 years
(median: 53 years) and 5 patients were younger than 50 years.
The duration of MS in these patients ranged from 4 to 35
years (considering those with known year of MS onset). Of
the 15 patients with PML, 2 presented with confounding
medical conditions (one with previous cancer and one patient
with ulcerative colitis with prior immunosuppressive ther-
apy). In addition, there were 2 patients who had received
therapy with natalizumab; however, the contributory role of
ﬁngolimod in the occurrence of PML could not be excluded in
these cases. The ﬁrst patient had previous natalizumab ex-
posure for 10 months, which was discontinued for 7 months,
and then the patient received ﬁngolimod treatment for 38
Glossary
CI = conﬁdence interval; JCV = John Cunningham virus; MS = multiple sclerosis; PML = progressive multifocal
leukoencephalopathy.
e1816 Neurology | Volume 90, Number 20 | May 15, 2018 Neurology.org/N
Table Case details of patients with MS who developed PML after fingolimod treatment
Age
range, y Sex
MS duration
(at time
of PML
diagnosis), y
Prior treatment for MS;
duration of washout of
prior treatment
Fingolimod
exposure,
mo
Compatible clinical
features
Compatible MRI
findings CSF PCR for JCV
Clinical
symptoms/
MRI findings/
CSF PCR for JCV
Certainty
of PML
diagnosis ALC, cells/μL
45–50 M 5 Interferon β-1a and
corticosteroids; washout after
steroids 7 mo
52 Asymptomatic Positive Positive (local lab
and NIH)
−/+/+ Probable 240–890
50–55 M 14 Interferon β-1b; washout
period a few days
30 Walking instability, motor
clumsiness, cognitive
symptoms
Positive Positive (local lab
and NIH)
+/+/+ Definite 200–550
50–55 F 19 Glatiramer acetate,
corticosteroids, interferon
β-1b; washout period
unknown
35 Unusual memory problems,
later significant confusion and
slurred speech
Positive Positive (local lab
and NIH)
+/+/+ Definite 400–1,000
55–60 F 15 Interferon β-1a; washout
period unknown
54 Cognitive disorder, struggled
to finish thoughts and
misused words, fleeting visual
hallucinations
Positive Positive (local lab
and NIH)
+/+/+ Definite 200–670
50–55 F At least 8 y
(exact duration
unknown)
Natalizumab (duration 10
mo); washout period 7 mo
39 Weakness on right side of
body, difficulty speaking,
cognitive disorder, memory
impairment, aphasia
Positive Positive +/+/+ Definite 300–500
60–65 F 4 Interferon β-1b; washout
period 9 mo
29 Cognitive decline, especially
speech loss, forgetfulness
MRI findings were
not typical; however,
PML could not be
ruled out
Positive (local lab
and NIH)
+/−/+ Probable 411–580
30–35 F 20 Interferon β-1b, interferon
β-1a, glatiramer acetate;
washout period unknown
46 Right-sided hemiplegia,
inappetence, loss of
sensation, aphasia, visual and
auditory hallucinations
Positive Positive (local lab
and NIH)
+/+/+ Definite 160–2,400
60–65 F 23 Interferon β-1a; washout
period unknown
45 Concentration deficits and
muscular weakness
Positive First sample
positive, second
sample (4 mo
later) negative
+/+/+ Definite 300–700
50–55 F 14 Interferon β-1a, 10 y before
fingolimod
18 Sensory deficits, hemiparesis,
cognitive impairment,
personality changes, aphasia,
visual impairment, inability to
speak, right-sided weakness
and monoplegia, cortical
blindness
Positive Positive +/+/+ Definite Reported that
there was no
decrease in
ALC
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Table Case details of patients with MS who developed PML after fingolimod treatment (continued)
Age
range, y Sex
MS duration
(at time
of PML
diagnosis), y
Prior treatment for MS;
duration of washout of
prior treatment
Fingolimod
exposure,
mo
Compatible clinical
features
Compatible MRI
findings CSF PCR for JCV
Clinical
symptoms/
MRI findings/
CSF PCR for JCV
Certainty
of PML
diagnosis ALC, cells/μL
55–60 F 19 Switched from fingolimod to
natalizumab after washout
period of 4 wk. On therapy
with natalizumab for 3 mo at
the time of PML diagnosis
57 Personality changes and
unspecified psychiatric
disorder
Positive Positive +/+/+ Definite Unknown
50–55 M 11 Interferon β-1a, interferon
β-1b; washout period
unknown
52 Severe visual disturbance in
posterior area on both sides
Positive Positive +/+/+ Definite 460–840
45–50 M 14 Interferon β-1a, interferon
β-1b, prednisolone; washout
period unknown
44 Aphasia and higher brain
dysfunction, abnormal
speech, ataxia, seizure,
cognitive disorder, and
paralysis
Positive Positive +/+/+ Definite >200
40–45 F Unknown Glatiramer acetate, interferon
β-1a; washout period
unknown
65 Muscular weakness, cognitive
loss, gait disturbance
MRI atypical for PML Positive (local lab
and NIH)
+/−/+ Probable 150 (;3 mo
before PML
diagnosis)
70–75 F 35 Glatiramer acetate, interferon
β-1a; washout period
unknown
58 Progressive dysarthria,
dizziness, ataxia, dysphasia,
hemiparesis, memory
impairment
Positive Positive (local lab) +/+/+ Definite 420–2,300
45–50 F 16 Glatiramer acetate, 4 y
corticosteroid pulse therapy;
washout period unknown
84 Worsening gait, cognitive
deficits, psychomotor
retardation, dysarthria,
hemiparesis
Positive Positive (local lab) +/+/+ Definite 362–970
Abbreviations: ALC = absolute lymphocyte count; JCV = John Cunningham virus; MS = multiple sclerosis; PML = progressive multifocal leukoencephalopathy.
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months before PML diagnosis. The second patient was re-
ceiving ﬁngolimod for 4 years, 6 months, which was dis-
continued to start natalizumab and was diagnosed with PML 3
months later. Fourteen of the 15 patients were exposed to
ﬁngolimod for >2 years. Based on the available reported
absolute lymphocyte counts in 14 of 15 patients, 4 of the
patients exhibited grade 4 lymphopenia (≤200 cells/μL).
Previous MS treatments included natalizumab, interferons,
corticosteroids, and glatiramer acetate, with no clinically
identiﬁable patterns.
Virologic characteristics
To date, there is only limited sequence information on the
JCVs associated with PML in ﬁngolimod-treated patients with
MS who developed PML.
PML clinical features and diagnosis
Heralding manifestations of PML at the time of clinical pre-
sentations included walking instability, weakness, memory
problems, confusion, dysarthria, visual hallucinations, cogni-
tive impairment, speech disturbances, concentration deﬁcits,
and visual impairment. One patient was clinically asymp-
tomatic at presentation, and the disorder was diagnosed ra-
diographically. No identiﬁable pattern was observed in clinical
symptoms at presentation.
Brain MRIs were consistent with PML in 13 of the 15 cases
and showed varying presentations, ranging from few but
extending lesions to multiple lesions extending into adjacent
lobes, cortical, subcortical, and juxtacortical regions, and
sometimes ill-deﬁned lesions, described with and without
microcysts. Some images showed strong hyperintense
diﬀusion-weighted imaging signals, whereas others were
without clear diﬀusion signals.
PCR results for JCV DNA in the CSF were positive in all 15
patients when tested at local laboratories and/or at the NIH
reference laboratory (Bethesda, MD). Serology for serum
JCV antibodies was reported for 8 of the 15 patients and was
positive in all.
Treatment and clinical outcome
Treatment with ﬁngolimod was discontinued in all patients,
and subsequent therapies for PML included meﬂoquine,
mirtazapine, and cidofovir in varying combinations. Three of
the PML cases were fatal. Most patients were reported to be
clinically stable or with slightly improving neurologic func-
tions or with deﬁcits including aphasia, mobility, and
cognition.
Discussion
In total, 15 patients with PML occurring in association with
ﬁngolimod administration alone were identiﬁed in the
Novartis safety database, including 12 “deﬁnite” and 3
“probable” cases, by August 2017. This included 6 cases that
have been published in the literature.13–18 The overall rate of
PML with ﬁngolimod treatment is estimated to be <1:10,000
patients, which was considered low risk in a recent article that
classiﬁed the risk of PML with current disease-modifying
therapies.19 The current estimated risk of PML with ﬁngoli-
mod treatment is 0.069 (95% CI: 0.039–0.114) per 1,000
patients and the incidence rate is 3.12/100,000 patient-years.
There are limitations for these risk estimates in that they are
solely based on the PML cases spontaneously reported to
Novartis from the postmarketing setting. Another potential
limitation is the estimate of patient exposure data, which are
derived from sales data. PML is a rare, serious opportunistic
infection with high awareness in theMS community; thus, the
probability of physicians reporting these cases is good. The
reporting rate over time has remained constant, thus sug-
gesting that cases of PML are being reported.
In a recent review,19 the risk of PML stratiﬁed by various
disease-modifying therapies used in patients with MS sug-
gested that natalizumab is associated with a signiﬁcantly
higher risk of PML. Fingolimod and dimethyl fumarate are
associated with signiﬁcantly lower risks. Alemtuzumab,
mitoxantrone, rituximab, and teriﬂunomide have a potential
risk of PML because all of these agents are associated with the
risk of PML when used in treatment regimens/indications
other than MS or have a related compound with which PML
has been observed. For newer compounds, such as daclizu-
mab and ocrelizumab, clinical experience is very limited and
the associated PML risk is unknown. The current risk of PML
with ﬁngolimod is very low; to date, only 15 cases have been
reported. Moreover, the few cases observed and evaluated so
far do not allow the identiﬁcation of any evidence-based
speciﬁc guidance to form monitoring and risk-mitigation
strategies for ﬁngolimod. However, certain risk mitigation
strategies have been proposed for other drugs with a larger
number of such cases or a potentially clearer correlation with
their mode of action, such as routine JCV antibody testing or
speciﬁc lymphocyte cutoﬀs. However, the value of such
guidance systems and their ability to prevent additional PML
cases is yet to be proven. So far, the risk stratiﬁcation algo-
rithm has not led to any marked reduction in the incidence of
PML in natalizumab-treated patients.20 Another previous
report suggested that, although a decrease in the incidence
of PML has not been noted, the rate of incidence increase
has certainly reduced signiﬁcantly between 2013 and 2016,
after the introduction of the Stratify JCV assay.21 Never-
theless, JCV antibody status should be retested regularly
considering the false-negative rates and the potential for
seroconversion.22,23
The number of PML cases reported so far with ﬁngolimod is
too low to trigger any speciﬁc interventions at this point in
time. Guidelines that are not evidence-based may result in an
additional burden for patients with uncertain beneﬁts, in-
cluding the risk of inappropriate modiﬁcation of an eﬀective
MS therapy, which in itself carries the risk of increasing
morbidity in such patients. At present, no PML risk
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stratiﬁcation methodology has been identiﬁed for patients
treated with ﬁngolimod. However, risk mitigation is focused
on increased awareness and education of patients and pre-
scribers regarding such cases because, in most instances, early
diagnosis and appropriate management are key to improved
therapeutic outcomes.
The clinical signs and symptoms of PML often resemble those
observed with an MS relapse; however, in contrast to an MS
relapse, these tend to be slowly and persistently progressive in
nature. Physicians should keep this in mind when in-
vestigating patients for PML and must look for features that
distinguish PML from other diﬀerential diagnoses including
MS. In a PML case series consisting of 28 patients,24 typical
clinical presentation included neurobehavioral, motor, lan-
guage, and visual symptoms, with cognitive changes being
more prominent. Acute or subacute cognitive changes, lan-
guage disturbances, and seizures should serve as “red ﬂags” for
the possibility of PML. Optic neuritis and myelopathy would
not be anticipated as clinical manifestations of PML.
MRI scans oﬀer a sensitive tool in the diagnosis of PML.
Typical PML lesions are diﬀuse, subcortical, and located ex-
clusively in the white matter. These lesions appear as single or
multiple hyperintense areas in T2-weighted images, which
become conﬂuent and large with disease progression. MRI
contrast enhancement is believed to be minimal or absent in
PML25; however, in AIDS-associated PML, 10% of patients
exhibited contrast enhancement on CT scans and 15% on
MRI with gadolinium.26 In natalizumab-associated PML, 43%
of cases showed gadolinium contrast enhancement at the time
of diagnosis.24 Although contrast enhancement alone cannot
be used as a feature to distinguish an MS relapse from PML,
patterns of contrast enhancement, the nature and location of
the lesions, and the presence of a dark rim around the lesions
on susceptibility weighted imaging or gradient echo imaging
may be helpful in distinguishing the demyelinating lesions of
PML from those of MS.27,28
As of August 2017, approximately 217,000 patients have been
treated with ﬁngolimod in both clinical trials and post-
marketing settings, and the total patient exposure exceeds
480,000 patient-years. Although the risk of PML with ﬁngo-
limod treatment is considered very low, vigilance toward PML
is required for all patients irrespective of the low risk. The
current understanding of the mechanism of action of ﬁngo-
limod does not provide a convincing causal link between
ﬁngolimod treatment and the incidence of PML. Fingolimod
has been shown to prevent the egress of CCR7+ve naive
T cells and central memory T cells from lymph nodes, sparing
CCR7−ve eﬀector memory T cells.29 The redistribution of
CD4+ central memory T cells from circulation to lymphatic
organs may contribute to the development of PML. In some
cases, because of its partial sequestration of eﬀector memory
T cells, ﬁngolimod may have a contributory role to other
factors in reducing immune response to JCV reactivation.
Isolating and fully characterizing the viruses in cases of
ﬁngolimod-associated PML may assist in understanding the
disease pathogenesis with ﬁngolimod.
Based on available data, there appear to be no clinically or
radiographically unique features of ﬁngolimod-associated
PML. The sex distribution is concordant with the overall
ﬁngolimod-treated population. Ten of the 15 patients were
older than 50 years at the time of PML diagnosis. Although an
exact relationship with ﬁngolimod treatment duration cannot
be elucidated, all 15 cases occurred after 18months or more of
treatment. There appears to be no correlation with profound
lymphopenia and lymphocyte subsets (CD4, CD8, and CD4/
8 ratios) in ﬁngolimod-treated patients, and this is not be-
lieved to be informative of PML risk. Treating physicians
should be vigilant for signs and symptoms suggestive of PML
in all patients who are being treated with ﬁngolimod. As soon
as PML is suspected, the drug should be discontinued until it
has been ruled out. Early diagnosis is critical for better clinical
outcomes. Unfortunately, there is no established treatment
for PML,30 and at this point of time, no treatment recom-
mendations can be made based on the limited number of
cases seen.
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Study question
What is the estimated risk and incidence of progressive
multifocal leukoencephalopathy (PML) after ﬁngolimod
treatment?
Summary answer
There is a low risk of PML after ﬁngolimod treatment in the
absence of prior natalizumab treatment.
What is known and what this paper adds
Evidence suggests an increased risk of PML in patients
with multiple sclerosis who are treated with immunosup-
pressive or immunomodulatory agents. The present
study determined the risk of PML after ﬁngolimod use
and suggests that ﬁngolimod-associated PML is relatively
rare and does not have unique clinical or radiographic
features.
Participants and setting
The study identiﬁed 15 patients with ﬁngolimod-associated
PML (12 deﬁnite cases and 3 probable cases) in the overall
population of patients treated with ﬁngolimod as documented
in the Novartis safety database.
Design, size, and duration
Safety database data were used to generate a risk estimate and
incidence of PML among patients treated with ﬁngolimod.
Patients with ﬁngolimod-associated PML were characterized
in terms of age, disease characteristics, comorbidities, and
previous medications including natalizumab treatment.
Primary outcomes
Three of the PML cases were fatal. Most patients were
reported to be clinically stable; had slightly improving neu-
rologic functions; or had deﬁcits including aphasia, mobility,
and cognition.
Main results and the role of chance
The estimated risk of PML in patients treated with ﬁngolimod
was 0.069 per 1000 patients (95% CI: 0.039–0.114) with an
incidence of 3.12 per 100,000 patient-years (95% CI:
1.75–5.15). Among 15 patients who developed PML, 11 were
women and 14 had received ﬁngolimod treatment for >2 years.
Two patients had a history of natalizumab treatment; however
the contributory role of ﬁngolimod could not be excluded. No
patient exhibited sustained grade 4 lymphopenia.
Bias, confounding, and other reasons
for caution
Risk estimation in this study was solely based on cases of PML
that were spontaneously reported to Novartis during post-
market surveillance. Additionally, patient exposure data were
estimated from both clinical trial data and estimated world-
wide sales volume (kilogram of active substance).
Generalizability to other populations
The results of the present study are generalizable to all
patients receiving treatment with ﬁngolimod.
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Age range
(y)
Fingolimod exposure
(mo) Certainty of PML diagnosis
Median: 53 Ranged from 18 to 65 All but one patient was
symptomatic at the time of
diagnosis
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